Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease

Drug Name

Yupelri™ (revefenacin)

Developers

Theravance Biopharma, Mylan

Therapy Class

Nebulised bronchodilator

Product Description

Long-acting muscarinic antagonist

Current Indication

Chronic obtrusive pulmonary disease (COPD)

Market Sector

Respiratory

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top